Semaglutide for Weight Loss
The most widely prescribed GLP-1 medication for weight loss and type 2 diabetes management.
Medically reviewed by GlobalGLP1 Editorial Team • Updated April 2026 • Sources: FDA prescribing information, peer-reviewed clinical trials
Overview
Semaglutide is a GLP-1 receptor agonist that mimics the natural incretin hormone GLP-1, which regulates appetite and blood sugar. Originally developed for type 2 diabetes (Ozempic), it was later approved at a higher dose for chronic weight management (Wegovy). Semaglutide has become the most recognized name in the GLP-1 weight loss category, with clinical trials showing average weight loss of 15-17% of body weight.
How Semaglutide Works
Semaglutide works by binding to GLP-1 receptors in the brain, pancreas, and gut. In the brain, it reduces appetite and food cravings by acting on the hypothalamus. In the pancreas, it stimulates insulin secretion and reduces glucagon release (blood sugar control). In the gut, it slows gastric emptying, helping you feel full longer after meals.
FDA Approvals
Ozempic
Type 2 diabetes mellitus
0.25 mg, 0.5 mg, 1 mg, 2 mg weekly injection
Rybelsus
Type 2 diabetes mellitus
3 mg, 7 mg, 14 mg daily oral tablet
Wegovy
Chronic weight management
0.25 mg to 2.4 mg weekly injection (escalating dose)
Wegovy HD
Chronic weight management (higher dose)
7.2 mg weekly injection
Dosing & Administration
Dose escalation is critical to minimize GI side effects. Most weight loss occurs at the maintenance dose. Do not skip the escalation period. The higher-dose Wegovy HD (7.2 mg) was FDA-approved in March 2026 for patients who may benefit from additional weight loss beyond the standard 2.4 mg dose.
Weight Loss Efficacy
In the STEP 1 trial, participants on Wegovy 2.4 mg lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% with placebo. About one-third of participants lost 20% or more of their body weight.
A1C Reduction: 1.0-1.8% A1C reduction (Ozempic, for diabetes)
Side Effects
Common Side Effects
- Nausea (most common, usually resolves)
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Headache
- Fatigue
- Injection site reactions
Serious (Rare)
- Pancreatitis (rare)
- Gallbladder disease
- Thyroid C-cell tumors (boxed warning, observed in rodents)
- Hypoglycemia (when combined with insulin or sulfonylureas)
- Kidney injury (due to dehydration from GI effects)
- Allergic reactions
Managing side effects: Most GI side effects improve with slow dose escalation. Eating smaller meals, staying hydrated, and avoiding fatty foods can help. If nausea persists, your provider may slow the escalation schedule.
Cost & Savings
Savings programs: Novo Nordisk offers savings cards for eligible commercially insured patients. NovoCare patient assistance program available for uninsured/underinsured patients.
Who Should Not Take Semaglutide
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to semaglutide
- Pregnancy or planning to become pregnant
- History of pancreatitis (use with caution)
Cardiovascular Effects
The SELECT trial studied semaglutide 2.4 mg in over 17,600 adults with overweight/obesity and established cardiovascular disease but without diabetes. Over a mean follow-up of 39.8 months, semaglutide reduced heart attack, stroke, and cardiovascular death by 20% compared to placebo. This led to an expanded FDA indication for Wegovy to reduce cardiovascular risk.
What this means for you: Semaglutide is the first GLP-1 medication with proven cardiovascular benefit in patients without diabetes. This is particularly relevant for patients with both obesity and heart disease.
Timeline: What to Expect
Most patients notice decreased hunger and food cravings. Portion sizes naturally decrease.
Measurable weight loss begins as doses escalate. Average 2-4% body weight lost during escalation phase.
Maintenance dose reached. Consistent weight loss of 1-2 lbs per week. Most GI side effects have resolved.
Average 10-15% body weight lost. Blood pressure, cholesterol, and blood sugar improvements measurable.
Weight loss plateau at 15-17% average. Metabolic health markers stabilized. Maintenance phase begins.
Drug Interactions
Significantly increases hypoglycemia risk. Insulin dose reduction of 20-50% is often needed when starting semaglutide.
Delayed gastric emptying may affect absorption timing of oral drugs. Take oral medications at least 1 hour before semaglutide injection day meals.
INR should be monitored more frequently when starting or changing semaglutide dose, as delayed gastric emptying may alter warfarin absorption.
Delayed gastric emptying could theoretically reduce absorption. Use backup contraception during initial dose escalation or switch to non-oral methods.
Special Populations
Contraindicated. Stop semaglutide at least 2 months before planned conception due to its long half-life. Animal studies showed embryotoxicity.
No dose adjustment needed for mild-to-moderate renal impairment. Use caution in severe impairment (eGFR <15) as nausea/vomiting can worsen dehydration and kidney function.
No dose adjustment required. Semaglutide is not primarily metabolized by the liver.
No dose adjustment needed. Clinical trials included patients up to 75 years. Monitor for dehydration risk as older adults may be more susceptible to GI fluid losses.
Wegovy is FDA-approved for adolescents aged 12+ with obesity (BMI >=95th percentile). The STEP TEENS trial showed 16.1% BMI reduction. Dosing schedule is the same as adults.
After Stopping Treatment
In the STEP 1 trial extension, participants who stopped semaglutide after 68 weeks regained about 11.6 percentage points of their 17.3% weight loss over the following year. Metabolic improvements (blood sugar, blood pressure) also partially reversed.
Mitigation strategies: Gradual dose tapering (rather than abrupt stop), established exercise habits, dietary counseling, and transition to lower-cost maintenance strategies can reduce regain. Some providers recommend long-term low-dose maintenance.
Frequently Asked Questions
Both contain semaglutide but at different doses and for different FDA-approved uses. Ozempic (max 2 mg/week) is approved for type 2 diabetes. Wegovy (max 2.4 mg/week) is approved for weight management. The higher Wegovy dose produces greater weight loss.
Most people notice reduced appetite within 1-2 weeks. Significant weight loss typically begins after reaching the maintenance dose (8-20 weeks, depending on the formulation). Full weight loss effects are usually seen over 12-18 months.
Yes. Wegovy is FDA-approved specifically for weight management in adults with BMI 30+ or BMI 27+ with at least one weight-related condition, regardless of diabetes status.
Studies show that most people regain some weight after stopping semaglutide, typically about two-thirds of the weight lost within one year. This is why many providers recommend long-term use and emphasize building sustainable diet and exercise habits while on the medication.
Compounded semaglutide is not FDA-approved and quality varies between pharmacies. The FDA has issued warnings about some compounded semaglutide products. If choosing compounded, ensure the pharmacy is 503B-registered and your provider monitors your treatment.
Moderate alcohol consumption is generally acceptable, but alcohol can worsen nausea and GI side effects. It also adds empty calories that may slow weight loss. If you have diabetes, alcohol can affect blood sugar levels unpredictably.
Wegovy HD is a higher-dose formulation of semaglutide approved by the FDA in March 2026. It allows dose escalation up to 7.2 mg weekly for patients who may benefit from additional weight loss beyond the standard 2.4 mg. In the STEP UP trial, the 7.2 mg dose produced an average weight loss of 20.7%. Your provider can determine if the higher dose is appropriate for you.
Compare Semaglutide providers by pricing, telehealth availability, and patient ratings.
Search Semaglutide Clinics →Find Semaglutide Clinics by State
Ready to start Semaglutide?
Search our directory of 2,770 GLP-1 clinics. Filter by medication, insurance, and telehealth availability.
Medical Disclaimer: This guide is for informational purposes only and is not medical advice. All clinical data is sourced from FDA prescribing information and published peer-reviewed trials. Individual results vary. Always consult a qualified healthcare provider before starting, stopping, or switching any medication.